{"citation":"Zavis, GLP-1 and Peptides Monitor, registries read on 19 October 2026; US approvals in the 90 days to that date. https://www.zavis.ai/intelligence/glp-1-and-peptides-monitor-october-2026","id":"glp1-peptides","title":"GLP-1 and Peptides Monitor","asOf":"2026-10-19","period":"registries read on 19 October 2026; US approvals in the 90 days to that date","source":"ClinicalTrials.gov (US National Library of Medicine), openFDA (US Food and Drug Administration), the European Medicines Agency's medicines data and the World Health Organization","method":"GLP-1 and related medicines are matched by non-proprietary name (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide and investigational medicines such as retatrutide and orforglipron). A study counts for a GCC country when it lists a site there. US approvals are Drugs@FDA submissions approved in the last 90 days for applications containing these medicines. Shortage entries are the FDA drug shortage list. Registered-study counts are ClinicalTrials.gov searches by name; 'with results posted' means results are on the registry. 'US approval on record' means Drugs@FDA holds at least one application for the substance.","caveats":["A registered study is not evidence that a medicine works or is safe; it shows research activity. Counts are matched by name and can include studies where the substance is a comparator.","The FDA shortage list describes the US market, not supply in the UAE or the GCC.","Peptides can be sold under names that differ from those registered; counts cover the names shown.","This monitor reports records only. It is not medical advice; decisions about any medicine belong with a licensed doctor."],"tables":[{"key":"peptide_evidence","caption":"Registered studies on ClinicalTrials.gov: GLP-1 medicines and other peptides","columns":["Substance","Registered studies worldwide","With results posted","US approval on record (Drugs@FDA)"],"rows":[["Semaglutide",788,109,"Yes"],["Tirzepatide",303,47,"Yes"],["Tesamorelin",24,10,"Yes"],["Sermorelin",27,11,"Yes"],["Thymosin beta-4 (TB-500)",18,8,"No"],["BPC-157",4,0,"No"],["Ipamorelin",3,0,"No"],["GHK-Cu (copper peptide)",3,0,"No"],["CJC-1295",1,0,"No"]]},{"key":"gcc_by_country","caption":"Studies of GLP-1 and related medicines with a site in each GCC country","columns":["Country","Studies (all time)","Recruiting or active now"],"rows":[["United Arab Emirates",15,1],["Saudi Arabia",15,5],["Qatar",2,1],["Kuwait",8,4],["Bahrain",0,0],["Oman",0,0]]},{"key":"gcc_by_medicine","caption":"GCC studies by medicine","columns":["Medicine","Studies (all time)","Recruiting or active now"],"rows":[["semaglutide",12,2],["liraglutide",9,1],["tirzepatide",5,2],["dulaglutide",3,0],["survodutide",3,2],["exenatide",2,0],["lixisenatide",2,0],["orforglipron",1,1],["cagrilintide",1,0]]},{"key":"gcc_active","caption":"GLP-1 and related studies recruiting or active at GCC sites","columns":["Registry ID","Medicines","Lead sponsor","Phase","Status","GCC countries"],"rows":[["NCT07613307","orforglipron","Eli Lilly and Company","Phase 3","Recruiting","United Arab Emirates, Saudi Arabia"],["NCT07614412","semaglutide","Ministry of Health, Saudi Arabia","Phase 2","Not yet recruiting","Saudi Arabia"],["NCT07574723","tirzepatide","Dasman Diabetes Institute","Not applicable","Recruiting","Kuwait"],["NCT07096908","tirzepatide","Dasman Diabetes Institute","Phase 4","Recruiting","Kuwait"],["NCT06885736","Class named, no medicine","Dasman Diabetes Institute","Not applicable","Recruiting","Kuwait"],["NCT06632444","survodutide","Boehringer Ingelheim","Phase 3","Recruiting","Saudi Arabia"],["NCT06632457","survodutide","Boehringer Ingelheim","Phase 3","Recruiting","Saudi Arabia"],["NCT06571383","semaglutide","Novo Nordisk A/S","Phase 4","Active not recruiting","Saudi Arabia"],["NCT06374875","Class named, no medicine","The Cleveland Clinic","Phase 4","Recruiting","Kuwait"],["NCT02879409","liraglutide","Weill Cornell Medical College in Qatar","Not applicable","Active not recruiting","Qatar"]]},{"key":"fda_recent","caption":"US FDA approvals for GLP-1 medicines in the last 90 days","columns":["Date","Medicine","Application","Approval","Category","Submissions"],"rows":[["2 October 2026","Exenatide synthetic (exenatide)","ANDA206697","Supplement","Labeling",3],["27 August 2026","Ozempic (semaglutide)","NDA209637","Supplement","Labeling",1],["27 August 2026","Mounjaro (tirzepatide)","NDA215866","Supplement","Efficacy",2],["26 August 2026","Zepbound (tirzepatide)","NDA217806","Supplement","Efficacy",1],["4 August 2026","Foundayo (orforglipron)","NDA220934","Supplement","Labeling",1]]},{"key":"fda_shortages","caption":"GLP-1 medicines on the US FDA drug shortage list","columns":["Medicine","Presentation","Status","Last updated"],"rows":[["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)","Current","22 September 2026"],["Liraglutide Injection","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)","Current","22 September 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)","Current","14 October 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)","Current","27 August 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)","Current","27 August 2026"],["Liraglutide Injection","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)","Current","22 September 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)","Current","14 October 2026"],["Liraglutide Injection","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)","Current","22 September 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)","Current","22 September 2026"],["Liraglutide Injection","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)","To Be Discontinued","25 August 2026"],["Liraglutide Injection","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)","To Be Discontinued","14 May 2026"],["Semaglutide Tablet","Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)","To Be Discontinued","4 June 2026"],["Semaglutide Tablet","Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)","To Be Discontinued","4 June 2026"],["Semaglutide Tablet","Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)","To Be Discontinued","4 June 2026"]]},{"key":"eu_products","caption":"GLP-1 and related medicines in the EU's centralised register","columns":["Medicine","Active substance","Status","First authorised","Last updated"],"rows":[["Foundayo","Orforglipron hemicalcium","Opinion","Not yet","Not stated"],["Ablymico","liraglutide","Authorised","15 July 2026","25 August 2026"],["Liraglutide STADA","liraglutide","Authorised","15 July 2026","25 August 2026"],["Kayshild","semaglutide","Authorised","26 March 2026","9 April 2026"],["Kyinsu","insulin icodec;semaglutide","Authorised","24 November 2025","12 February 2026"],["Mounjaro","tirzepatide","Authorised","15 September 2022","8 October 2026"],["Wegovy","semaglutide","Authorised","6 January 2022","21 September 2026"],["Rybelsus","semaglutide","Authorised","3 April 2020","22 April 2026"],["Ozempic","semaglutide","Authorised","8 February 2018","25 August 2026"],["Suliqua","insulin glargine;lixisenatide","Authorised","11 January 2017","8 September 2026"],["Saxenda","liraglutide","Authorised","23 March 2015","31 July 2025"],["Trulicity","dulaglutide","Authorised","21 November 2014","30 January 2026"],["Xultophy","insulin degludec;liraglutide","Authorised","18 September 2014","28 November 2024"],["Lyxumia","lixisenatide","Withdrawn","31 January 2013","5 February 2026"],["Bydureon","exenatide","Withdrawn","17 June 2011","2 October 2026"]]},{"key":"gcc_obesity","caption":"Adults with obesity in the GCC (WHO, age-standardised)","columns":["Country","Adults with obesity (%)","Year"],"rows":[["Qatar",42,"2024"],["Kuwait",40.4,"2024"],["Saudi Arabia",40.1,"2024"],["Bahrain",34.9,"2024"],["United Arab Emirates",31.6,"2024"],["Oman",30.5,"2024"]]}]}